Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Jennifer Diamond

Concepts (284)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Triple Negative Breast Neoplasms
16
2024
197
6.550
 Why?
Breast Neoplasms
23
2023
2142
4.350
 Why?
Antineoplastic Agents
23
2023
2061
2.590
 Why?
Immunoconjugates
7
2023
103
2.570
 Why?
Antineoplastic Combined Chemotherapy Protocols
19
2023
1565
2.440
 Why?
Pyrimidines
9
2021
459
2.370
 Why?
Receptor, ErbB-2
11
2023
326
1.940
 Why?
Protein Kinase Inhibitors
10
2022
891
1.720
 Why?
Piperazines
4
2020
342
1.670
 Why?
Paclitaxel
6
2022
217
1.600
 Why?
Neoplasms
14
2022
2470
1.590
 Why?
Camptothecin
9
2023
109
1.590
 Why?
Pyrazoles
6
2021
405
1.390
 Why?
Quinoxalines
2
2020
65
1.300
 Why?
Antibodies, Monoclonal, Humanized
10
2024
759
1.280
 Why?
Azepines
3
2020
89
1.240
 Why?
Ovarian Neoplasms
4
2020
490
1.210
 Why?
Histone Deacetylase Inhibitors
4
2024
209
1.190
 Why?
Cyclin-Dependent Kinase 4
2
2018
44
1.100
 Why?
Cyclin-Dependent Kinase 6
2
2018
40
1.090
 Why?
Neutropenia
4
2022
136
0.890
 Why?
Gene Expression Regulation, Neoplastic
5
2020
1356
0.780
 Why?
Xenograft Model Antitumor Assays
11
2021
814
0.750
 Why?
beta Catenin
2
2020
223
0.750
 Why?
Breast Neoplasms, Male
2
2018
29
0.740
 Why?
Female
49
2024
68776
0.690
 Why?
Cancer Care Facilities
1
2020
32
0.690
 Why?
Chemotherapy, Adjuvant
4
2023
381
0.690
 Why?
Maximum Tolerated Dose
9
2022
193
0.690
 Why?
Benzoxazoles
1
2020
20
0.680
 Why?
Receptors, Estrogen
3
2021
426
0.680
 Why?
Carcinoma, Lobular
2
2018
48
0.680
 Why?
eIF-2 Kinase
1
2019
30
0.650
 Why?
Lymphocytes, Tumor-Infiltrating
2
2020
211
0.640
 Why?
Tumor Microenvironment
4
2024
634
0.630
 Why?
Anthracyclines
3
2023
49
0.610
 Why?
Humans
62
2024
129650
0.600
 Why?
Taxoids
3
2023
98
0.600
 Why?
Drug Resistance, Neoplasm
4
2020
759
0.570
 Why?
Wnt Signaling Pathway
1
2019
170
0.570
 Why?
Carcinoma, Ductal, Breast
1
2018
82
0.560
 Why?
Aurora Kinase A
4
2020
55
0.560
 Why?
Aged
22
2023
22103
0.560
 Why?
Trastuzumab
4
2023
101
0.560
 Why?
Pyrazines
2
2018
86
0.530
 Why?
Myocardial Infarction
1
2023
1022
0.510
 Why?
Colonic Neoplasms
1
2018
243
0.510
 Why?
Pyridines
2
2018
478
0.510
 Why?
Tumor Suppressor Protein p53
4
2024
511
0.500
 Why?
Neoadjuvant Therapy
1
2018
383
0.490
 Why?
Nuclear Proteins
2
2023
663
0.490
 Why?
Angiopoietin-1
1
2015
11
0.480
 Why?
Angiopoietin-2
1
2015
15
0.480
 Why?
Uterine Cervical Neoplasms
1
2017
233
0.440
 Why?
Medicare
4
2023
720
0.440
 Why?
Cell Line, Tumor
9
2022
3215
0.430
 Why?
Colorectal Neoplasms
5
2022
752
0.430
 Why?
Middle Aged
23
2021
31154
0.410
 Why?
Antibodies, Monoclonal
4
2024
1367
0.410
 Why?
Dose-Response Relationship, Drug
6
2022
2012
0.400
 Why?
Tumor Suppressor Proteins
1
2015
317
0.400
 Why?
Cell Proliferation
8
2020
2391
0.400
 Why?
Proto-Oncogene Proteins c-met
1
2013
74
0.400
 Why?
Antineoplastic Agents, Immunological
3
2019
181
0.390
 Why?
Recombinant Fusion Proteins
1
2015
643
0.390
 Why?
Point Mutation
1
2013
225
0.390
 Why?
Adult
24
2024
35576
0.390
 Why?
Treatment Outcome
12
2022
10230
0.380
 Why?
Triazoles
1
2013
152
0.370
 Why?
Angiogenesis Inhibitors
3
2018
220
0.370
 Why?
Mice, Nude
6
2020
683
0.360
 Why?
Carcinoma, Renal Cell
1
2013
180
0.350
 Why?
Mitochondria
1
2017
877
0.350
 Why?
Clinical Trials, Phase I as Topic
2
2020
50
0.340
 Why?
Heart Failure
1
2023
2150
0.340
 Why?
Neoplasm Recurrence, Local
4
2021
964
0.340
 Why?
Histones
3
2023
588
0.340
 Why?
Neoplasm Metastasis
4
2020
610
0.330
 Why?
Genes, BRCA2
1
2009
24
0.330
 Why?
Genes, BRCA1
1
2009
32
0.330
 Why?
Biomarkers, Tumor
2
2014
1181
0.320
 Why?
Molecular Targeted Therapy
3
2019
390
0.320
 Why?
Aged, 80 and over
8
2020
7086
0.320
 Why?
BRCA2 Protein
1
2009
53
0.320
 Why?
Pregnancy Complications, Neoplastic
1
2009
53
0.310
 Why?
Neoplasm Staging
5
2021
1295
0.310
 Why?
Lung Neoplasms
2
2024
2344
0.310
 Why?
Thrombophilia
1
2009
81
0.310
 Why?
Kidney Neoplasms
1
2013
350
0.310
 Why?
Apoptosis
7
2024
2503
0.300
 Why?
Quinolines
2
2021
156
0.300
 Why?
Aromatase Inhibitors
2
2018
51
0.300
 Why?
Receptors, Progesterone
2
2021
343
0.280
 Why?
DNA-Binding Proteins
1
2015
1443
0.280
 Why?
Mice
9
2021
16937
0.260
 Why?
Models, Biological
1
2014
1722
0.260
 Why?
Doxorubicin
3
2024
325
0.250
 Why?
Liver Neoplasms
1
2009
640
0.220
 Why?
Cyclophosphamide
2
2018
232
0.220
 Why?
Radiosurgery
2
2019
321
0.220
 Why?
Disease Models, Animal
3
2021
4063
0.210
 Why?
United States
5
2023
13903
0.210
 Why?
Animals
11
2021
35361
0.200
 Why?
Cyclin-Dependent Kinase 9
1
2022
10
0.200
 Why?
Biopsy
2
2018
1097
0.190
 Why?
Histone Deacetylase 1
1
2022
24
0.190
 Why?
Aurora Kinases
2
2012
29
0.190
 Why?
Administration, Oral
3
2022
786
0.190
 Why?
G2 Phase Cell Cycle Checkpoints
3
2022
45
0.190
 Why?
Disease Progression
4
2019
2635
0.190
 Why?
Topoisomerase I Inhibitors
2
2022
16
0.190
 Why?
Fluorouracil
1
2022
199
0.190
 Why?
Acetylation
1
2022
246
0.180
 Why?
Biliary Tract Neoplasms
1
2021
25
0.180
 Why?
Arrhythmias, Cardiac
1
2023
317
0.180
 Why?
Androstadienes
1
2021
106
0.180
 Why?
Carboplatin
1
2021
140
0.170
 Why?
Diarrhea
2
2019
180
0.170
 Why?
Heterografts
1
2021
131
0.170
 Why?
Necrosis
2
2019
232
0.170
 Why?
Hospitals, University
1
2021
179
0.170
 Why?
Drug Administration Schedule
3
2017
769
0.170
 Why?
Fatigue
2
2022
318
0.170
 Why?
Immunotherapy
2
2023
592
0.170
 Why?
Histone Deacetylases
1
2022
212
0.170
 Why?
Clinical Trials as Topic
3
2016
1004
0.170
 Why?
Male
13
2021
63681
0.170
 Why?
Mechanistic Target of Rapamycin Complex 2
1
2020
62
0.170
 Why?
Benzodiazepines
1
2021
136
0.160
 Why?
Immune System
1
2021
175
0.160
 Why?
Mechanistic Target of Rapamycin Complex 1
1
2020
119
0.160
 Why?
Myeloid Cell Leukemia Sequence 1 Protein
1
2019
40
0.160
 Why?
Kaplan-Meier Estimate
1
2021
857
0.160
 Why?
Tumor Cells, Cultured
1
2020
940
0.150
 Why?
Albumins
1
2019
103
0.150
 Why?
Maintenance Chemotherapy
1
2018
22
0.150
 Why?
Aquaporin 4
1
2019
95
0.150
 Why?
Vascular Endothelial Growth Factor A
2
2018
530
0.150
 Why?
Aminopyridines
1
2018
97
0.150
 Why?
Nausea
1
2018
110
0.150
 Why?
Antibodies, Bispecific
1
2018
49
0.140
 Why?
Mice, Inbred BALB C
1
2020
1245
0.140
 Why?
Drug Therapy, Combination
1
2020
1040
0.140
 Why?
Radiotherapy, Adjuvant
1
2018
210
0.140
 Why?
Breast
1
2018
153
0.140
 Why?
Purines
1
2018
172
0.140
 Why?
Benzimidazoles
1
2018
162
0.140
 Why?
Mastectomy
1
2018
131
0.140
 Why?
Topotecan
1
2017
12
0.140
 Why?
Imidazoles
1
2018
234
0.140
 Why?
Isoflavones
1
2017
25
0.140
 Why?
Calcium-Binding Proteins
1
2018
210
0.140
 Why?
Survival Analysis
1
2020
1274
0.140
 Why?
Carbolines
1
2017
30
0.140
 Why?
Heterocyclic Compounds, 4 or More Rings
1
2017
19
0.130
 Why?
Programmed Cell Death 1 Receptor
1
2019
232
0.130
 Why?
Inhibitory Concentration 50
2
2016
86
0.130
 Why?
Nanoparticles
1
2021
374
0.130
 Why?
Neoplasms, Radiation-Induced
1
2016
71
0.130
 Why?
Cell Survival
1
2019
1086
0.130
 Why?
Insulin-Like Growth Factor I
1
2018
307
0.130
 Why?
Hypertension
2
2018
1242
0.130
 Why?
GPI-Linked Proteins
1
2016
68
0.120
 Why?
Adaptor Proteins, Signal Transducing
1
2018
399
0.120
 Why?
Neoplasms, Second Primary
1
2016
106
0.120
 Why?
Tumor Protein p73
1
2015
14
0.120
 Why?
Antibodies, Neoplasm
1
2015
35
0.120
 Why?
Carcinoma, Non-Small-Cell Lung
1
2024
1052
0.120
 Why?
Risk Reduction Behavior
1
2016
209
0.120
 Why?
Phosphorylation
1
2019
1713
0.120
 Why?
Hodgkin Disease
1
2016
134
0.120
 Why?
Retrospective Studies
3
2021
14518
0.120
 Why?
Maytansine
1
2014
16
0.110
 Why?
Demography
1
2015
279
0.110
 Why?
Brain Edema
1
2014
60
0.110
 Why?
Survival Rate
2
2019
1877
0.110
 Why?
Drug Interactions
1
2015
394
0.110
 Why?
Protein Kinases
1
2015
318
0.110
 Why?
Randomized Controlled Trials as Topic
1
2019
1368
0.110
 Why?
Sulfones
1
2014
108
0.100
 Why?
Threonine
1
2013
44
0.100
 Why?
Glycine
1
2014
165
0.100
 Why?
Drug Evaluation, Preclinical
1
2013
171
0.100
 Why?
Tumor Stem Cell Assay
1
2012
32
0.100
 Why?
Analgesics, Opioid
1
2021
913
0.100
 Why?
Time Factors
2
2020
6556
0.100
 Why?
Drug Design
1
2013
156
0.100
 Why?
Methionine
1
2013
158
0.100
 Why?
Heterozygote
1
2013
272
0.100
 Why?
Disease-Free Survival
1
2014
648
0.100
 Why?
Treatment Failure
1
2013
340
0.100
 Why?
In Situ Hybridization, Fluorescence
1
2013
315
0.100
 Why?
Neovascularization, Pathologic
1
2013
297
0.090
 Why?
Computational Biology
1
2015
599
0.090
 Why?
Cell Transformation, Neoplastic
1
2013
328
0.090
 Why?
Risk Assessment
1
2020
3240
0.090
 Why?
Cluster Analysis
1
2012
482
0.090
 Why?
Carcinoma in Situ
1
2011
45
0.090
 Why?
Receptor Protein-Tyrosine Kinases
1
2013
231
0.090
 Why?
Cellular Senescence
1
2012
181
0.090
 Why?
Vascular Endothelial Growth Factor Receptor-2
1
2010
84
0.090
 Why?
Colorado
1
2020
4421
0.090
 Why?
Mutation
2
2012
3717
0.080
 Why?
Sequence Analysis, DNA
1
2013
779
0.080
 Why?
Tumor Burden
1
2010
286
0.080
 Why?
Brain Neoplasms
2
2019
1171
0.080
 Why?
Pregnancy Trimester, Second
1
2009
77
0.080
 Why?
Keratinocytes
1
2010
242
0.080
 Why?
Mastectomy, Segmental
1
2009
85
0.080
 Why?
Pregnancy Trimester, First
1
2009
138
0.080
 Why?
Poly(ADP-ribose) Polymerase Inhibitors
1
2009
90
0.080
 Why?
Apoptosis Regulatory Proteins
1
2009
182
0.080
 Why?
Lymph Node Excision
1
2009
164
0.070
 Why?
Risk
1
2009
854
0.070
 Why?
Infusions, Intravenous
2
2019
400
0.070
 Why?
Cell Adhesion Molecules
2
2019
173
0.070
 Why?
Risk Factors
1
2020
9765
0.070
 Why?
Prognosis
2
2018
3794
0.070
 Why?
Gene Expression Profiling
1
2012
1706
0.060
 Why?
Cell Cycle Proteins
2
2023
586
0.060
 Why?
Antigens, Neoplasm
2
2019
309
0.060
 Why?
CD8-Positive T-Lymphocytes
2
2023
857
0.060
 Why?
Cell Cycle
2
2018
592
0.060
 Why?
Combined Modality Therapy
2
2019
1206
0.050
 Why?
Mesylates
1
2022
7
0.050
 Why?
Ataxia Telangiectasia Mutated Proteins
1
2022
66
0.050
 Why?
Signal Transduction
2
2014
4925
0.050
 Why?
Clinical Protocols
1
2023
255
0.050
 Why?
Ligands
1
2024
622
0.050
 Why?
RNA, Small Interfering
1
2024
587
0.050
 Why?
Chimerism
1
2021
31
0.050
 Why?
Lymphoid Tissue
1
2021
67
0.040
 Why?
Lymphocyte Subsets
1
2021
84
0.040
 Why?
Liver
1
2009
1839
0.040
 Why?
Mice, SCID
1
2021
351
0.040
 Why?
SEER Program
1
2021
206
0.040
 Why?
Hormones
1
2020
140
0.040
 Why?
Mice, Inbred NOD
1
2021
588
0.040
 Why?
M Phase Cell Cycle Checkpoints
1
2018
24
0.040
 Why?
Infant, Newborn
1
2009
5762
0.040
 Why?
Tissue Distribution
1
2018
315
0.040
 Why?
Anemia
1
2019
160
0.040
 Why?
Pregnancy
1
2009
6402
0.030
 Why?
Cetuximab
1
2016
94
0.030
 Why?
Retreatment
1
2016
70
0.030
 Why?
Cyclin-Dependent Kinase Inhibitor p21
1
2016
117
0.030
 Why?
Neoplasm Transplantation
1
2016
257
0.030
 Why?
Drug Screening Assays, Antitumor
1
2016
195
0.030
 Why?
Platinum
1
2016
44
0.030
 Why?
Hematopoietic Stem Cell Transplantation
1
2021
573
0.030
 Why?
History, Ancient
1
2015
52
0.030
 Why?
Transcription Factors
1
2023
1651
0.030
 Why?
Proto-Oncogene Proteins p21(ras)
1
2016
259
0.030
 Why?
Databases, Genetic
1
2015
232
0.030
 Why?
DNA Damage
1
2017
384
0.030
 Why?
Mice, Knockout
1
2021
2871
0.030
 Why?
Biomarkers
2
2016
3973
0.030
 Why?
Opioid-Related Disorders
1
2021
484
0.030
 Why?
Phenotype
1
2021
3076
0.020
 Why?
Drug Combinations
1
2013
330
0.020
 Why?
Drug-Related Side Effects and Adverse Reactions
1
2015
253
0.020
 Why?
Intracellular Signaling Peptides and Proteins
1
2015
442
0.020
 Why?
Immunohistochemistry
1
2016
1698
0.020
 Why?
Biopsy, Needle
1
2011
189
0.020
 Why?
Cohort Studies
1
2021
5420
0.020
 Why?
Transcription, Genetic
1
2017
1418
0.020
 Why?
Enzyme Inhibitors
1
2014
827
0.020
 Why?
HT29 Cells
1
2010
36
0.020
 Why?
Proto-Oncogene Proteins
1
2014
638
0.020
 Why?
ErbB Receptors
1
2013
607
0.020
 Why?
Protein-Tyrosine Kinases
1
2013
432
0.020
 Why?
Ki-67 Antigen
1
2010
109
0.020
 Why?
Patient Selection
1
2013
663
0.020
 Why?
Capillary Permeability
1
2010
139
0.020
 Why?
Follow-Up Studies
1
2018
4897
0.020
 Why?
Patient Satisfaction
1
2013
634
0.020
 Why?
Membrane Proteins
1
2015
1119
0.020
 Why?
Positron-Emission Tomography
1
2010
288
0.020
 Why?
Algorithms
1
2015
1622
0.020
 Why?
Magnetic Resonance Imaging
1
2019
3408
0.020
 Why?
Tomography, X-Ray Computed
1
2016
2535
0.020
 Why?
Adolescent
1
2024
20393
0.010
 Why?
Brain
1
2014
2679
0.010
 Why?
Young Adult
1
2014
12426
0.010
 Why?
Diamond's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (284) concept(s)
_
Co-Authors Expand Description
See all (68) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)